Camptosar Injection, Solution
Product Images NDC 0009-7529

14 FDA label images from Pharmacia & Upjohn Company Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Camptosar (NDC 0009-7529). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pharmacia & Upjohn Company Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Camptosar 01)

Chemical Structure (Camptosar 01)
Chemical structure of irinotecan hydrochloride, the active ingredient in Camptosar injection. The structure includes molecular groups and denotes associated hydrochloride and hydrate components.*
FDA Label Image

Figure 1 (Camptosar 02)

Figure 1 (Camptosar 02)
A survival curve chart comparing First-Line Irinotecan/5-FU/LV versus 5-FU/LV alone over a period of up to 42 months. The vertical axis represents probability from 0.0 to 1.0, and the horizontal axis shows months. The curves illustrate higher survival probability with Irinotecan/5-FU/LV compared to 5-FU/LV, with a noted statistical significance (p<0.05).*
FDA Label Image

Figure 2 (Camptosar 03)

Figure 2 (Camptosar 03)
A survival curve chart titled 'Figure 2. Survival First-Line Irinotecan/5-FU/LV vs 5-FU/LV Study 2.' It plots probability on the vertical axis against months on the horizontal axis, comparing survival probabilities over time between two treatments: Irinotecan/5-FU/LV and 5-FU/LV. The Irinotecan/5-FU/LV curve shows generally higher survival probabilities than the 5-FU/LV curve across the 30-month period. A note indicates the use of a log-rank test with p<0.05 significance.*
FDA Label Image

Figure 3 (Camptosar 04)

Figure 3 (Camptosar 04)
A Kaplan-Meier survival curve comparing the probability of survival over months between two groups: Irinotecan and BSC (best supportive care). The chart shows the number of participants, median follow-up time, and median survival time for each group, with a p-value indicating statistical significance.*
FDA Label Image

Figure 4 (Camptosar 05)

Figure 4 (Camptosar 05)
A Kaplan-Meier survival probability curve comparing irinotecan and 5-FU over a follow-up period of 21 months. The x-axis represents time in months, and the y-axis shows probability from 0 to 1. The graph includes sample sizes and median follow-up times for each treatment group.*
FDA Label Image

Logo (Camptosar 06)

Logo (Camptosar 06)
Label displaying Pfizer Injectables logo and distribution information for Camptosar (irinotecan hydrochloride) injection. The distributor is Pharmacia & Upjohn Company LLC, a division of Pfizer Inc, located in New York, NY 10017.*
FDA Label Image

Principal Display Panel (100 mg/5 mL Vial Label)

Principal Display Panel (100 mg/5 mL Vial Label)
Label for Camptosar injection, irinotecan hydrochloride, 100 mg/5 mL (20 mg/mL) solution for intravenous use. The single-dose Cytosafe vial is labeled as a cytotoxic agent, with storage instructions to protect from light and freezing and to store at controlled room temperature (15°C to 30°C). Distributed by Pharmacia & Upjohn Co, a division of Pfizer Inc, made in Australia.*
FDA Label Image

Principal Display Panel (100 mg/5 mL Vial Carton)

Principal Display Panel (100 mg/5 mL Vial Carton)
Camptosar 100 mg/5 mL (20 mg/mL) injection carton label for intravenous use containing irinotecan hydrochloride. The single-dose vial comes from Pharmacia & Upjohn Company LLC, a Pfizer division. Label emphasizes cytotoxic agent caution, storage instructions, and disposal warnings, with branding and regulatory information.*
FDA Label Image

Principal Display Panel (40 mg/2 mL Vial Label)

Principal Display Panel (40 mg/2 mL Vial Label)
Label for Camptosar (irinotecan HCl injection) showing 40 mg/2 mL concentration (equivalent to 20 mg/mL). The label states it is a hazardous drug for intravenous use only, in a single-dose vial. Distributed by Pharmacia & Upjohn Company LLC, a Pfizer subsidiary in New York, NY. Includes barcode and fields for lot and expiration information.*
FDA Label Image

Principal Display Panel (40 mg/2 mL Carton)

Principal Display Panel (40 mg/2 mL Carton)
Packaging label for Camptosar (irinotecan hydrochloride) injection 40 mg/2 mL (20 mg/mL) in a single-dose vial. The label states 'For Intravenous Use Only' and 'Must Dilute Before Use.' It includes storage instructions, hazard warnings, and is distributed by Pharmacia & Upjohn Company LLC, a Pfizer subsidiary. The label indicates it is a hazardous drug and intended for hospital use.*
FDA Label Image

Principal Display Panel (100 mg/5 mL Label)

Principal Display Panel (100 mg/5 mL Label)
Camptosar 100 mg/5 mL injection label for irinotecan hydrochloride, a 20 mg/mL sterile aqueous intravenous solution. The label includes storage instructions to keep at 15° to 30°C and protects from light and freezing. It is marked for single-dose use, hazardous drug warning, and is distributed by Pharmacia & Upjohn Company LLC, a Pfizer subsidiary.*
FDA Label Image

Principal Display Panel (100 mg/5 mL Carton)

Principal Display Panel (100 mg/5 mL Carton)
Camptosar 100 mg/5 mL (20 mg/mL) injection solution label for a 5 mL single-dose vial. The product contains irinotecan hydrochloride for intravenous use only and must be diluted before use. Packaging includes storage instructions, dosage recommendations, and hazardous drug warnings. Distributed by Pharmacia & Upjohn Company LLC, a Pfizer subsidiary.*
FDA Label Image

Principal Display Panel (300 mg/15 mL Label)

Principal Display Panel (300 mg/15 mL Label)
Camptosar 300 mg/15 mL (20 mg/mL) injection, solution label for intravenous use by Pharmacia & Upjohn Company LLC, a Pfizer subsidiary. The label states it is a sterile aqueous solution, single-dose vial, with storage instructions, hazardous drug warning, and space for lot and expiration information.*
FDA Label Image

Principal Display Panel (300 mg/15 mL Carton)

Principal Display Panel (300 mg/15 mL Carton)
Camptosar 300 mg/15 mL (20 mg/mL) injection label for intravenous use, containing irinotecan hydrochloride. The label indicates a single-dose vial with instructions to discard unused portions and emphasizes the need for dilution before use. It includes storage conditions, handling warnings, and is labeled by Pharmacia & Upjohn Company LLC, a Pfizer subsidiary.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.